Clinical Trial Update: Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a PD-1 inhibitor in combination with autologous cell immunotherapy for metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Autologous cell immunotherapy (autologous cell immunotherapy)
• PD-1 inhibitor

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN